CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography (CAPTAIN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00500344
Verified February 2009 by Washington University School of Medicine. Recruitment status was: Active, not recruiting
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ability to provide written informed consent and comply with study assessments for the full duration of the study
Age ≥ 50 years
Treatment naive AMD patients that are determined to be candidates for ranibizumab
Visual acuity 20/40 to 20/320
Prior enrollment in the study
Previous therapy for AMD or other retinal diseases which may be used in the treatment of AMD
Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed
Any condition that would interfere with the ERG recording (such as media opacities including lens or corneal opacity)
Concurrent eye disease in the study eye that could compromise visual acuity (such as diabetic retinopathy, advanced glaucoma)
Any condition causing the patient to have a significant tremor that would interfere with the patient's ability to remain still during the ERG (such as Parkinson's disease)
Participation in another simultaneous medical investigation or trial